What do systematic reviews say?

Dornase alfa vs placebo or no dornase alfa treatment

• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 318 participants
  Moderate

Dornase alfa vs placebo or no dornase alfa treatment

Dornase alfa leads to higher relative mean percentage change in FVC (% predicted) at 6 months compared with placebo or no dornase alfa treatment (high certainty).

• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  MD 3.8 [2.62, 4.98]
  1 study · 647 participants
  High

Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy

Summary of findings: single showed no clear difference in change in FEV1 % predicted at end of antibiotic course: absolute… compared with combination intravenous anti‐pseudomonal antibiotic therapy (low certainty).

• Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
  MD 5.25
  2 studies · 93 participants
  Low

Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy

The review found no eligible studies for this question.

• Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Dornase alfa vs after airway clearance techniques

It is very uncertain whether inhalation of dornase alfa before changes FEV1 (% predicted) change from baseline compared with after airway clearance techniques (very low certainty).

• Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
  MD 0.83
  102 participants
  Very low

Dornase alfa vs after airway clearance techniques

Inhalation of dornase alfa before showed no clear difference in FVC (% predicted) change from baseline compared with after airway clearance techniques (low certainty).

• Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
  MD 1.06
  77 participants
  Low

Dornase alfa vs after airway clearance techniques

Inhalation of dornase alfa before showed no clear difference in FEF25-75 (% predicted) compared with after airway clearance techniques (low certainty).

• Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  25 participants
  Low

Morning vs evening inhalation of dornase alfa

Morning showed no clear difference in FEV1 (% predicted) change from baseline compared with evening inhalation of dornase alfa (low certainty).

• Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  25 participants
  Low

Morning vs evening inhalation of dornase alfa

Morning showed no clear difference in FVC (% predicted) change from baseline compared with evening inhalation of dornase alfa (low certainty).

• Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  25 participants
  Low

Morning vs evening inhalation of dornase alfa

The review found no eligible studies for this question.

• Timing of dornase alfa inhalation for cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Standard rhGH vs placebo

• Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 43 participants
  Low

High‐dose rhGH vs placebo

• Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 41 participants
  Low

High‐dose rhGH vs placebo

• Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 41 participants
  Low

Standard rhGH vs placebo

• Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 43 participants
  Low

High‐dose rhGH vs standard‐dose rhGH

• Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 42 participants
  Low

High‐dose rhGH vs standard‐dose rhGH

• Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 42 participants
  Low

Standard rhGH vs no treatment

• Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 19 participants
  Very low

Standard rhGH vs no treatment

• Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 19 participants
  Very low

Angiotensin‐converting enzyme inhibitors vs placebo

• Angiotensin‐converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 22 participants
  Very low

Autogenic drainage vs conventional physiotherapy

• Autogenic drainage for airway clearance in cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 54 participants
  Very low